uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
46.23
-1.63 (-3.41%)
Sep 2, 2026, 4:00 PM EDT - Market closed
uniQure Revenue
uniQure had revenue of $5.84M in the quarter ending June 30, 2026, with 11.00% growth. This brings the company's revenue in the last twelve months to $18.67M, up 30.24% year-over-year. In the year 2025, uniQure had annual revenue of $16.10M, down -40.64%.
Revenue (ttm)
$18.67M
Revenue Growth
+30.24%
P/S Ratio
171.74
Revenue / Employee
$84,489
Employees
221
Market Cap
3.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | -11.02M | -40.64% |
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 14.52M | 137.27% |
| Dec 31, 2015 | 10.58M | 4.44M | 72.25% |
| Dec 31, 2014 | 6.14M | 2.09M | 51.74% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 68.42K | -174.98K | -71.89% |
| Dec 31, 2005 | 243.40K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 606.33M |
| Arcutis Biotherapeutics | 463.98M |
| Zai Lab | 449.61M |
| Beam Therapeutics | 156.04M |
| NewAmsterdam Pharma Company | 7.12M |
| Immunome | 4.02M |
| Celldex Therapeutics | 158.00K |
QURE News
- 20 hours ago - uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
- 21 hours ago - uniQure submits biologics license application to FDA for ifezuntirgene inilparvo - TheFly
- 22 hours ago - uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease - GlobeNewsWire
- 22 hours ago - uniQure resumed with an Outperform at William Blair - TheFly
- 4 weeks ago - uniQure price target lowered to $60 from $65 at Barclays - TheFly
- 5 weeks ago - Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130 - TheFly
- 5 weeks ago - uniQure upgraded to Outperform from Peer Perform at Wolfe Research - TheFly
- 5 weeks ago - uniQure Earnings Call Transcript: Q2 2026 - Transcripts